
    
      This is a randomized, double-blind, placebo-controlled study designed to evaluate the safety,
      tolerability, and efficacy of multiple doses of sarizotan in patients with Rett syndrome with
      respiratory abnormalities. The study participants will be randomized to either sarizotan
      between 2 and 10 mg bid or placebo bid, based on age and weight criteria.
    
  